Brand name · Ophthalmic / Anti-VEGF
Lucentis (Ranibizumab) J-Code / HCPCS Code
In short
Lucentis is billed under HCPCS J2778 — Injection, ranibizumab, 0.1 mg. One billing unit is 0.1 mg.
Ranibizumab biosimilars and the ranibizumab implant have their own HCPCS codes.
Reference
- Code
- J2778 — Injection, ranibizumab, 0.1 mgMed-Code curated
- Billing unit
- 0.1 mg
- Same code in the directory
- Ranibizumab
- Pharmacologic class
- Vascular Endothelial Growth Factor InhibitorFrom the FDA listings below
- Labelers
- Genentech, Inc.
- J-code category
- Ophthalmic / Anti-VEGF
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Lucentisranibizumab | Ranibizumab 10 mg/mL | Injection, SolutionIntravitreal | Genentech, Inc. | 50242-080 |
| Lucentisranibizumab | Ranibizumab 6 mg/mL | Injection, SolutionIntravitreal | Genentech, Inc. | 50242-082 |
NDCs billed under J2778
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J2778 for Lucentis and Lucentis PFS. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Lucentis | 50242-0080-03 | Genentech, Inc. | 0.05 | 5 |
| Lucentis PFS | 50242-0082-03 | Genentech, Inc. | 0.05 | 3 |